Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell-Mediated Antitumor Responses

William H D Hallett, Erik Ames, Maite Álvarez, Isabel Barao, Patricia A. Taylor, Bruce R. Blazar, William J Murphy

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Interleukin (IL)-2 has been extensively examined to promote clinical T and natural killer (NK) cell responses. Regulatory T cells (Tregs) have been shown to regulate many aspects of the immune system, including NK cell-mediated responses. We have demonstrated that in vivo administration of IL-2 led to activation and expansion of both NK cells and immunosuppressive Tregs. Therefore, we attempted to augment NK cell antitumor effects by concurrently depleting Tregs using anti-CD25. Increased NK cell activation by IL-2 was found to be correlated with an increase in classical, short-term NK cell in vitro killing assays regardless of the depletion of Tregs. But when splenocytes of the treated mice were used in long-term tumor outgrowth experiments, we observed that prior depletion of Tregs from IL-2 administration led to improved antitumor effects compared with either treatment alone. Importantly, these in vitro data are correlated with subsequent in vivo survival of leukemia-bearing mice, in which co-treatment of IL-2 with anti-CD25 led to significantly improved survival compared with mice treated with either IL-2 alone or with Treg depletion. Prior depletion of NK1.1+ cells, but not of CD8+ cells, completely abrogated all antitumor effects mediated by IL-2 and anti-CD25 combination therapy. These findings demonstrate that superior NK cell-mediated antileukemic effects can be achieved with IL-2 administration and concurrent depletion of CD25+ cells.

Original languageEnglish (US)
Pages (from-to)1088-1099
Number of pages12
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue number10
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Natural Killer Cells
Interleukin-2
Therapeutics
Natural Killer T-Cells
Regulatory T-Lymphocytes
Immunosuppressive Agents
Immune System
Leukemia
Neoplasms

Keywords

  • Natural killer cells
  • Regulatory T cells

ASJC Scopus subject areas

  • Transplantation

Cite this

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell-Mediated Antitumor Responses. / Hallett, William H D; Ames, Erik; Álvarez, Maite; Barao, Isabel; Taylor, Patricia A.; Blazar, Bruce R.; Murphy, William J.

In: Biology of Blood and Marrow Transplantation, Vol. 14, No. 10, 10.2008, p. 1088-1099.

Research output: Contribution to journalArticle

Hallett, William H D ; Ames, Erik ; Álvarez, Maite ; Barao, Isabel ; Taylor, Patricia A. ; Blazar, Bruce R. ; Murphy, William J. / Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell-Mediated Antitumor Responses. In: Biology of Blood and Marrow Transplantation. 2008 ; Vol. 14, No. 10. pp. 1088-1099.
@article{251d9230df024182ad1e358391846e7f,
title = "Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell-Mediated Antitumor Responses",
abstract = "Interleukin (IL)-2 has been extensively examined to promote clinical T and natural killer (NK) cell responses. Regulatory T cells (Tregs) have been shown to regulate many aspects of the immune system, including NK cell-mediated responses. We have demonstrated that in vivo administration of IL-2 led to activation and expansion of both NK cells and immunosuppressive Tregs. Therefore, we attempted to augment NK cell antitumor effects by concurrently depleting Tregs using anti-CD25. Increased NK cell activation by IL-2 was found to be correlated with an increase in classical, short-term NK cell in vitro killing assays regardless of the depletion of Tregs. But when splenocytes of the treated mice were used in long-term tumor outgrowth experiments, we observed that prior depletion of Tregs from IL-2 administration led to improved antitumor effects compared with either treatment alone. Importantly, these in vitro data are correlated with subsequent in vivo survival of leukemia-bearing mice, in which co-treatment of IL-2 with anti-CD25 led to significantly improved survival compared with mice treated with either IL-2 alone or with Treg depletion. Prior depletion of NK1.1+ cells, but not of CD8+ cells, completely abrogated all antitumor effects mediated by IL-2 and anti-CD25 combination therapy. These findings demonstrate that superior NK cell-mediated antileukemic effects can be achieved with IL-2 administration and concurrent depletion of CD25+ cells.",
keywords = "Natural killer cells, Regulatory T cells",
author = "Hallett, {William H D} and Erik Ames and Maite {\'A}lvarez and Isabel Barao and Taylor, {Patricia A.} and Blazar, {Bruce R.} and Murphy, {William J}",
year = "2008",
month = "10",
doi = "10.1016/j.bbmt.2008.08.001",
language = "English (US)",
volume = "14",
pages = "1088--1099",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell-Mediated Antitumor Responses

AU - Hallett, William H D

AU - Ames, Erik

AU - Álvarez, Maite

AU - Barao, Isabel

AU - Taylor, Patricia A.

AU - Blazar, Bruce R.

AU - Murphy, William J

PY - 2008/10

Y1 - 2008/10

N2 - Interleukin (IL)-2 has been extensively examined to promote clinical T and natural killer (NK) cell responses. Regulatory T cells (Tregs) have been shown to regulate many aspects of the immune system, including NK cell-mediated responses. We have demonstrated that in vivo administration of IL-2 led to activation and expansion of both NK cells and immunosuppressive Tregs. Therefore, we attempted to augment NK cell antitumor effects by concurrently depleting Tregs using anti-CD25. Increased NK cell activation by IL-2 was found to be correlated with an increase in classical, short-term NK cell in vitro killing assays regardless of the depletion of Tregs. But when splenocytes of the treated mice were used in long-term tumor outgrowth experiments, we observed that prior depletion of Tregs from IL-2 administration led to improved antitumor effects compared with either treatment alone. Importantly, these in vitro data are correlated with subsequent in vivo survival of leukemia-bearing mice, in which co-treatment of IL-2 with anti-CD25 led to significantly improved survival compared with mice treated with either IL-2 alone or with Treg depletion. Prior depletion of NK1.1+ cells, but not of CD8+ cells, completely abrogated all antitumor effects mediated by IL-2 and anti-CD25 combination therapy. These findings demonstrate that superior NK cell-mediated antileukemic effects can be achieved with IL-2 administration and concurrent depletion of CD25+ cells.

AB - Interleukin (IL)-2 has been extensively examined to promote clinical T and natural killer (NK) cell responses. Regulatory T cells (Tregs) have been shown to regulate many aspects of the immune system, including NK cell-mediated responses. We have demonstrated that in vivo administration of IL-2 led to activation and expansion of both NK cells and immunosuppressive Tregs. Therefore, we attempted to augment NK cell antitumor effects by concurrently depleting Tregs using anti-CD25. Increased NK cell activation by IL-2 was found to be correlated with an increase in classical, short-term NK cell in vitro killing assays regardless of the depletion of Tregs. But when splenocytes of the treated mice were used in long-term tumor outgrowth experiments, we observed that prior depletion of Tregs from IL-2 administration led to improved antitumor effects compared with either treatment alone. Importantly, these in vitro data are correlated with subsequent in vivo survival of leukemia-bearing mice, in which co-treatment of IL-2 with anti-CD25 led to significantly improved survival compared with mice treated with either IL-2 alone or with Treg depletion. Prior depletion of NK1.1+ cells, but not of CD8+ cells, completely abrogated all antitumor effects mediated by IL-2 and anti-CD25 combination therapy. These findings demonstrate that superior NK cell-mediated antileukemic effects can be achieved with IL-2 administration and concurrent depletion of CD25+ cells.

KW - Natural killer cells

KW - Regulatory T cells

UR - http://www.scopus.com/inward/record.url?scp=51649084785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649084785&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.08.001

DO - 10.1016/j.bbmt.2008.08.001

M3 - Article

C2 - 18804038

AN - SCOPUS:51649084785

VL - 14

SP - 1088

EP - 1099

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -